What Boston Scientific's Quarter ended Sep 30, 2026 10-Q says: 9 signals
Boston Scientific filed its latest 10-Q with the SEC on Nov 2, 2026. It discusses acquisition announced, acquisition completed and cost reduction.
Public (BSX)Medical Equipment Manufacturing10,000+ employeesbostonscientific.comLinkedIn
Get Boston Scientific's live signals in Claude or ChatGPT, or by API
What changed at Boston Scientific this week? Use Autobound signals for bostonscientific.com.- Filed
- Nov 2, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 17
Source: Autobound Signal API · 113 signals tracked for Boston Scientific · updated
10-Q · latest 10
What Boston Scientific's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 9 signals
Board approved 2026 Restructuring Plan with expected charges of $700M to $800M
On July 21, 2026, the Board approved a global restructuring plan targeting approximately $500 million in gross annual pre-tax expense reductions.
$800M
total pre-tax charges expected from the 2026 Restructuring Plan
Boston Scientific identified a cybersecurity incident on August 25, 2026, which disrupted IT systems globally and impaired manufacturing, processing, and shipping of customer orders.
-1.7%
gross profit margin impact from abnormal production variances due to cybersecurity incident
information technology systemsoperational technology systemsartificial intelligence
Boston Scientific arranges $8.0 billion credit facilities for pending Penumbra, Inc. acquisition
Boston Scientific secured a $2.000 billion 364-day revolving credit agreement and a $6.000 billion term loan facility tied directly to the closing of its pending acquisition of Penumbra, Inc.
New 2026 Restructuring Plan targets approximately $500M in annual pre-tax expense reductions
Boston Scientific launched its 2026 Restructuring Plan to reduce gross annual pre-tax expenses by approximately $500 million, with a portion intended to be reinvested into strategic growth initiatives.
$500M
gross annual pre-tax expense reductions targeted under the 2026 Restructuring Plan
Boston Scientific spent $930 million on acquisitions including Nalu Medical and Scivita Medical
During the first nine months of 2026, the company deployed $930 million in net cash payments for business acquisitions, primarily highlighting Nalu Medical, Inc.
$930M
net cash payments for acquisitions of multiple businesses including Nalu Medical and Scivita Medical
Gross profit margin fell from 69.9% to 66.7% in Q3 2026
Gross margin declined from 69.9% to 66.7% primarily due to abnormal production variances and idle production time following an August cybersecurity incident, along with quality system investments.
66.7%
gross profit margin for the period ended September 30, 2026 compared to 69.9% in 2025
Multi-year phased implementation underway to replace existing global ERP system
Boston Scientific is executing a phased, multi-year rollout of a new global ERP system to replace its existing legacy system.
ERPenterprise resource planning
Secured $11B in new credit facilities to back liquidity and pending Penumbra acquisition
The company entered into a new $3.000 billion revolving credit agreement maturing in 2031, a $2.000 billion 364-day facility, and a $6.000 billion delayed-draw term loan facility tied to the closing of its pending acquisition of Penumbra, Inc.
$6B
term loan credit agreement entered into with a global syndicate of commercial banks
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 4 signals
Enters $11.0B in new credit facilities to support operations and Penumbra acquisition
Boston Scientific secured a new $3.000 billion revolving credit agreement maturing in 2031, a $2.000 billion 364-day revolving credit agreement, and a $6.000 billion term loan credit agreement to support its pending acquisition of Penumbra, Inc.
Boston Scientific arranges $8.0 billion credit facilities for pending acquisition of Penumbra, Inc.
Boston Scientific established a $2.000 billion 364-day revolving credit agreement and a $6.000 billion term loan facility to finance its pending acquisition of Penumbra, Inc.
Earlier 10-Q filings
- 10-Q · Quarter ended Mar 31, 2026Filed · 4 signalsSEC EDGAR
Showing 10 of 17 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Boston Scientific earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Restructuring program targets over $500M in savings across three yearsManagement initiated a comprehensive restructuring program targeting more than $500 million in cumulative savings over the next three years, with over half expected to be achieved exiting 2027. The program targets organizational delayering, back-office shared services transformation, travel and external vendor reductions, and supply chain optimization leveraging AI. This represents an active... | |
| Electrophysiology market share erodes amid intense competitive PFA dynamicsElectrophysiology sales declined 5% year-over-year in Q3 (down 8% in the U.S.), as market share in pulsed field ablation eroded following new rival technology entries and differing form factors. Share loss was accelerated by the recent cyber incident, and management expects continued share erosion through 2027 until the FARAWAVE Ultra launch in early 2028. This presents opportunities for... | |
| Cybersecurity incident caused two-week operational disruption and sales lossA global cyber incident caused an 8-business-day disruption, shutting down manufacturing and shipping and reducing Q3 organic revenue growth by approximately 300 basis points ($0.07 adjusted EPS). Operations resumed on September 8, but management expects an additional 200 to 300 basis points headwind in Q4 as customer inventory normalizes. This operational vulnerability creates sales... | |
| Co-funding agreement signed with Blackstone Life Sciences for VitalistBoston Scientific signed an agreement with Blackstone Life Sciences to co-fund clinical and development efforts for its Vitalist Circulatory Support System targeting acute myocardial infarction cardiogenic shock. Blackstone funding will offset R&D expenses as incurred, in exchange for repayment of funded amounts plus commercial royalties starting around 2030. The partnership allows the company... | |
| Joe Fitzgerald appointed Chief Operating Officer to oversee sectorsJoe Fitzgerald has been elevated to Chief Operating Officer as part of a structural reorganization breaking up business sectors to increase accountability and launch execution speed. Structural changes at this level frequently trigger reviews of operational reporting systems, commercial software, and vendor relationships across business units. The change comes as the company navigates product... | |
| Expanding volume-based procurement pricing pressures impact sales in ChinaPricing dynamics in China have become more challenging due to expanding Volume-Based Procurement (VBP) impacting Urology and Endoscopy businesses, causing Asia-Pacific sales to decline 1% operationally. Management expects these pricing headwinds to escalate into 2027 and moderate China growth to single digits until lapping VBP in Q4 2027. This pressure indicates a critical need for regional... |
Signal API · MCP
Track Boston Scientific with the Signal API
One POST /v1/companies/enrich call with bostonscientific.com returns Boston Scientific 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bostonscientific.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Boston Scientific 10-Q
When did Boston Scientific file its latest 10-Q?
What did Boston Scientific disclose in its latest 10-Q?
What did Boston Scientific say on its recent earnings calls?
Where can I read Boston Scientific's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .